This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Verano Holdings Corp. (VRNOF) Soars 31.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Stryker (SYK) Launches Q Guidance System for Spine Applications
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.
Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod
by Zacks Equity Research
Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.
The Zacks Analyst Blog Highlights Microsoft, Danaher, Raytheon Technologies, Stryker Corporation and Vale
by Zacks Equity Research
Microsoft, Danaher, Raytheon Technologies, Stryker Corporation and Vale are included in this Analyst Blog.
Top Stock Reports for Microsoft, Danaher & Raytheon Technologies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Danaher Corporation (DHR) and Raytheon Technologies Corporation (RTX).
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Stryker's (SYK) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
Stryker (SYK) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of -0.88% and 0.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
Stryker (SYK) to Boost Presence in China Via Digital Healthcare
by Zacks Equity Research
Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.
The Zacks Analyst Blog Highlights Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker
by Zacks Equity Research
Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Top Research Reports for Microsoft, Amgen & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amgen Inc. (AMGN), and Honeywell International Inc. (HON).
TG Therapeutics (TGTX) Soars 18.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Stryker's (SYK) Q Guidance System Receives FDA Approval
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
The Zacks Analyst Blog Highlights Amazon.com, ConocoPhillips, Stryker, Chipotle Mexican Grill and ONEOK
by Zacks Equity Research
Amazon.com, ConocoPhillips, Stryker, Chipotle Mexican Grill and ONEOK have been included in this Analyst Blog.
Top Analyst Reports for Amazon, ConocoPhillips & Stryker
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), ConocoPhillips (COP), and Stryker Corporation (SYK).
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 2.07% and 1.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Apr 28 Earnings Roster: ABMD, SYK & More
by Trina Mukherjee
The MedTech companies' Q1 results are likely to reflect solid rebound in base business sales. Let's see how ABMD, SYK, BAX and DXCM are poised ahead of their earnings releases.
Stryker (SYK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) first-quarter results are likely to reflect strong segmental performances.
Stryker (SYK) Reports Next Week: What Awaits?
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Texas Instruments, Intuit, Lockheed Martin, ConocoPhillips and Stryker
by Zacks Equity Research
Texas Instruments, Intuit, Lockheed Martin, ConocoPhillips and Stryker are part of today's top Analyst Blog.
Top Stock Reports for Texas Instruments, Intuit & Lockheed Martin
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Intuit Inc. (INTU), and Lockheed Martin Corporation (LMT).